US3271450A - 2, 2'-(ethylenediimino)-di-1-butanols - Google Patents
2, 2'-(ethylenediimino)-di-1-butanols Download PDFInfo
- Publication number
- US3271450A US3271450A US432419A US43241965A US3271450A US 3271450 A US3271450 A US 3271450A US 432419 A US432419 A US 432419A US 43241965 A US43241965 A US 43241965A US 3271450 A US3271450 A US 3271450A
- Authority
- US
- United States
- Prior art keywords
- ethyl
- bis
- butanol
- aminoethanol
- ethylenediamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Definitions
- This invention relates to novel symmetrical ethylenediamines and, more particularly, is concerned with derivatives of N- [N'- a-ethyl-fl-hydroxyethyl -,8-aminoethyl] -,8- ethyl-,B-aminoethanol which may be represented by the following general formula:
- R and R are the same and are hydrogen, methyl or ethyl; and R and R are the same and are methyl, ethyl or benzyl.
- novel compounds of the present invention are, in general, white crystalline solids or colorless oils, soluble in lower alkanols and variably soluble in water, acetone, chloroform, ether, benzene, petroleum ether and the like.
- the acid-addition salts of the novel compounds of the present invention are, in general, soluble in water and hot alkanols, but relatively insoluble in non-polar organic solvents such as benzene, ether and the like.
- the nontoxic acid-addition salts of the novel symmetrical ethylenediamines of the present invention with a variety of organic and inorganic acids are also included within the scope of the invention.
- acid-addition salts formed by admixture of the organic free base with an acid are formed with such acids as sulfuric, phosphoric, hydrochloric, hydrobromic, citric, lactic, tartaric, acetic, benzoic, ascorbic and the like.
- the organic free bases are equivalent to their non-toxic acid-addition salts.
- novel compounds of the present invention are active against experimental human strain tuberculosis in mice. Furthermore, the chemical structures of these compounds are distinct from the drugs heretofore found effective against tuberculosis and should be particularly useful in treating resistant tuberculosis and also in combination.
- the organism used in the test is Mycobacterium tuberculosis (H37Rv).
- the test animals are white female mice.
- the test animals are infected with the organisms by administration intravenously of 0.2 ml. of a buffered saline suspension containing approximately 3,271,450 Patented Sept. 6, 1966 1.5 mg./ml., wet weight, of a 12 or 13 day culture of the test organism grown on solid Sautons medium composed of: 0.05 gm. iron ammonium citrate; 0.5 gm. dipotassium phosphate; 0.5 gm. magnesium sulfate; 2.0 gm. citric acid; 4.0 gm. asparagine; 35.0 ml. glycerine; dist. water q.s.
- mice During a one year experience with this test, the standard infection defined above caused a 99.5% mortality, in that 756 of the 760 infected untreated control mice died within 30 days, the normal period of the test. Routinely, each week 200-30O mice are given the standard infection and then segregated in a random manner into cages each of which holds five or ten mice. Four groups of five mice each are retained as untreated controls, and the remaining mice are used to ascertain drug activity.
- Drug treatment is administered orally as follows: A measured amount of the compound to be tested is mixed with a weighed amount of feed, and the test animals are allowed to feed at will for 14 days from the time of infection-t-he controls, of course, on untreated feed. All surviving animals are then allowed to feed at will on untreated feed for the remainder of the 30 day test period. A compound is judged active if it either saves 2 or more of the 5 mice in the test group, or prolongs average survival time by 4 or more days, compared to untreated controls.
- N-[N'-(oc -et'hyl-B-hydroxyethyl)43- aminoethyl]- ⁇ 3-ethyl-fl-aminoethanol may be readily prepared by the interaction of an ethylene dihalide with two equivalents of 2-amino-l-butanol.
- N,N'-dimethyl and N,N'-diethyl derivatives of N [N(cc ethyl-,B-hydroxyethyl)-fi-aminoethyl]-fi-ethyl- [i-aminoethanol may also be readily prepared by the interaction of an ethylene dihalide with two equivalents of 2- methylamino-l-butanol or Z-ethylamino-l-butanol, respectively. This preparative method is illustrated by Examples 1 and 3 hereinafter.
- N-[N-(a-ethyl-,H-hydroxyethyl)- ⁇ 3 aminoethyl]-, 3 ethyl-B-amino ethanol and its N,N'-dimethyl and N,N-diethyl derivatives may also be conveniently prepared by the interaction of glyoxal with 2-amino-1-butanol, 2-methylamino-1-butanol or 2-ethylamino-l-butanol, respectively, followed by reduction of the Schiif base intermediates with lithium aluminum hydride. This method is illustrated by Example 5 hereinafter.
- N,N-dimethyl derivative of N-[N'-(a-ethyl-flhydroxyethyl) -fi-aminoethyl] -/3-ethyl-fl-aminoethanol may also be readily prepared by treatment of N[N-(a-ethyl- B hydroxyethyl) B-aminoethyl]-[3-ethyl-,B-aminoethanol with formaldehyde in concentrated formic acid. This method is illustrated by Example 2 hereinafter.
- N,N diethyl derivative of N-[N-(a-ethyl-fl-hydroxyethyD-fl-aminoethyl]-,B-ethyl-fl-aminoethanol may also be readily prepared by treating the N-[N'(a-ethyl-,B-hydroxyethyl)-/3-aminoethyl]- ⁇ 3-ethyl-,B-aminoethanol with excess acetic anhydride and reducing the intermediate N,N',0,0- tetra-acetyl derivative with lithium aluminum hydride, the O-acetyl functions being removed during the reduction.
- Example 4 This method is illustrated by Example 4 hereinafter.
- the 0,0'-dimethyl, 0,0-diethyl and 0,0-dibenzyl derivatives of N-[N'-(oc ethyl B-hydroxyethyD-B-aminoethyl]-B ethyl-fl-aminoethanol, N-methyl-N- [N'-methyl- N'-(oc ethyl 18 hydroxyethyl)-fi-aminoethyl]-[i-ethyl- ⁇ 3- aminoethanol and N-ethyl-N- [N'-ethyl-N- a-ethyl-fi-hydroxyethyl -;3-aminoethy1] -,8-ethy1-B-aminoethanol may be readily prepared by treating the sodium salt of the appropriate ethylenediamine base with methyl iodide, ethyl iodide or benzyl chloride. This method is illustrated by Examples 6, 7, 8, 9 and 10
- the dosage units of the drug may contain other inert or medically active materials, for instance, when the dosage unit form is a tablet, pill or granules, there may also be present various binders, fillers or solid diluents. Suitable materials for this purpose may be, for example, starch such as corn starch or sugar such as lactose or sucrose. There may also be present various medically active materials such as, for example, p-amino salicyclic acid. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. The dosage unit form may also have present various flavors, oil of Wintergreen, and excipients such as dicalcium phosphate.
- pills or capsules may be coated with shellac, sugar or both.
- any material used in preparing the dosage unit form must be pharmaceutically pure and substantially nontoxic in the amounts employed.
- An alternate method of preparing the product of EX- ample 3 is to treat N-[N'-ol-ethyl-fi-hydroxyethyl)-,B- aminoethyl]-fl-ethyl-[3-aminoethanol with excess acetic anhydride to obtain the N,N,0,0'-tetra-acetyl derivative.
- this intermediate By reduction of this intermediate with lithium aluminum hydride in diethyl ether at the reflux temperature for a period of several hours, the desired N,N'-diethyl derivative is obtained, the O-acetyl functions being removed during the reaction.
- Example 6 -N ,N -bisa-m ethoxymethylpropyl ethy enediamine
- a solution of 21.0 g. of dextro 2,2'-(ethylenediimino)- di-l-butanol in 225 ml. of t-butanol was added a suspension of 9.50 g. of sodium hydride (51.5% NaH in oil) in 30 ml. of ether and the reaction mixture was heated to deflux for 1 hour whereby a clear solution was obtained. This was cooled to 35 C. with some solid forming. Dropwise addition of a solution of 28.0 g. of methyl iodide in 25 ml.
- Example 7 N,N'-bis- (ot-methoxymethylpropyl) ethylenediamine
- Example 6 was repeated but an equimolar amount of the racemic form was employed in place of the dextro starting material of that example. There was obtained the racemic N,N-bis-(a methoxymethylpropyl)ethylenediamine dihydrochloride as white crystals, M.P. 148- 150 C.
- Example 8N,N'-bis-(a-methoxymethylpropyl) ethylenediamine By replacing the dex-tro starting material employed in Example 6 by an equimolar quantity of the meso isomer and following substantially the same procedure described in Example 6, there was obtained the meso N,N'-biS-(ocmethoxymethylpropyl)ethylenediamine as a colorless oil, B.P. 144-146 C./13 mm.
- Example 9 N,N'-bis-( a-ethoxymethylpropyl ethylenediam'ine The procedure of Example 6 was repeated substituting an equimolar amount of ethyl iodide for the methyl iodide employed in that example. There was thus obtained on distillation dextro N,N-bis-(a-ethoxymethylpropyl) ethylenediamine, B. P. 157160 C./ 8 mm.
- Example 10 N,N'-bis-(ot-benzyloxymethylpropyl) ethylenediamine
- Example 11N,N-bis-(oz-methoxymethylpropyl) -N,N- dimelhylethylenediamine A solution of 4.1 g. of dl-2,2'-(ethylenediimino)-di-1- butanol in 20 ml. of hot toluene was added dropwise to a suspension of 0.96 g. of sodium hydride in 5 ml. of toluene, the temperature being kept at 100 C. After stirring this mixture for several hours at room temperature, a solution of 6.3 g. of dimethyl sulfate in 5 ml. of toluene was added slowly, keeping the temperature below 50 C. The resulting mixture was treated with water and the toluene layer separated.
- the water layer was extracted several times with methylene chloride and the combined extracts (toluene and CH Cl were dried over anhydrous sodium carbonate, and concentrated to 50 ml.
- the concentrate was extracted with dilute hydrochloric acid.
- the extract was basified, and the insoluble organic layer extracted into CH CI
- the extract was dried over anhydrous sodium carbonate, concentrated, and the residue distilled under reduced pressure to give the tetramethyl derivative as a liquid fraction, B.P. 95 C./0.01 mm.
- R and R are the same and are selected from the group consisting of hydrogen, methyl and ethyl, and R and R are the same and are selected from the group consisting of methyl, ethyl and benzyl; and the non-toxic acid-addition salts thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
United States Patent 3,271,450 2,2-(ETHYLENEDIIMINO)-DI-l-BUTANOLS Raymond George Wilkinson, Montvale, and Robert Gordon Shepherd, Ridgewood, N.J., assignors to American Cyanamid Company, New York, N.Y., a corporation of Maine No Drawing. Original application Jan. 23, 1962, Ser. No. 168,241, now Patent No. 3,176,040, dated Mar. 30, 1965. Divided and this application Feb. 12, 1965, Ser. No. 432,419
Claims priority, application Great Britain, Feb. 7, 1961,
4,517/ 61, Patent 961,317 10 Claims. (Cl. 260570.5)
This application is a division of our copending application Serial No. 168,241, filed January 23, 1962, and now US. Patent No. 3,176,040, which is a continuation-in-part of our application Serial No. 77,034, filed December 20, 1960, now abandoned, which is a continuation-in-part of our application Serial No. 33,399, filed June 2, 1960, now abandoned. Applicants claim priority under their British application Serial No. 4,517, filed February 7, 1961, now British Patent No. 961,317, for all that is disclosed therein which is not disclosed in their applications Serial No. 33,399 and Serial No. 77,034.
This invention relates to novel symmetrical ethylenediamines and, more particularly, is concerned with derivatives of N- [N'- a-ethyl-fl-hydroxyethyl -,8-aminoethyl] -,8- ethyl-,B-aminoethanol which may be represented by the following general formula:
wherein R and R are the same and are hydrogen, methyl or ethyl; and R and R are the same and are methyl, ethyl or benzyl.
The novel compounds of the present invention are, in general, white crystalline solids or colorless oils, soluble in lower alkanols and variably soluble in water, acetone, chloroform, ether, benzene, petroleum ether and the like. The acid-addition salts of the novel compounds of the present invention are, in general, soluble in water and hot alkanols, but relatively insoluble in non-polar organic solvents such as benzene, ether and the like. The nontoxic acid-addition salts of the novel symmetrical ethylenediamines of the present invention with a variety of organic and inorganic acids are also included within the scope of the invention. Thus, acid-addition salts formed by admixture of the organic free base with an acid, suitably in a neutral solvent, are formed with such acids as sulfuric, phosphoric, hydrochloric, hydrobromic, citric, lactic, tartaric, acetic, benzoic, ascorbic and the like. For purposes of this invention, the organic free bases are equivalent to their non-toxic acid-addition salts.
The novel compounds of the present invention are active against experimental human strain tuberculosis in mice. Furthermore, the chemical structures of these compounds are distinct from the drugs heretofore found effective against tuberculosis and should be particularly useful in treating resistant tuberculosis and also in combination.
therapy which is widely used in this field.
In testing the compounds of the present invention for anti-tuberculous activity the organism used in the test is Mycobacterium tuberculosis (H37Rv). The test animals are white female mice. The test animals are infected with the organisms by administration intravenously of 0.2 ml. of a buffered saline suspension containing approximately 3,271,450 Patented Sept. 6, 1966 1.5 mg./ml., wet weight, of a 12 or 13 day culture of the test organism grown on solid Sautons medium composed of: 0.05 gm. iron ammonium citrate; 0.5 gm. dipotassium phosphate; 0.5 gm. magnesium sulfate; 2.0 gm. citric acid; 4.0 gm. asparagine; 35.0 ml. glycerine; dist. water q.s.
During a one year experience with this test, the standard infection defined above caused a 99.5% mortality, in that 756 of the 760 infected untreated control mice died within 30 days, the normal period of the test. Routinely, each week 200-30O mice are given the standard infection and then segregated in a random manner into cages each of which holds five or ten mice. Four groups of five mice each are retained as untreated controls, and the remaining mice are used to ascertain drug activity.
Drug treatment is administered orally as follows: A measured amount of the compound to be tested is mixed with a weighed amount of feed, and the test animals are allowed to feed at will for 14 days from the time of infection-t-he controls, of course, on untreated feed. All surviving animals are then allowed to feed at will on untreated feed for the remainder of the 30 day test period. A compound is judged active if it either saves 2 or more of the 5 mice in the test group, or prolongs average survival time by 4 or more days, compared to untreated controls.
The following table summarizes the relative activity of typical compounds compared to p-aminosalicyclic acid (as 100%) based on the minimum quantities of compounds required to give the same response shown by p-aminosalicyclic acid.
The intermediate N-[N'-(oc -et'hyl-B-hydroxyethyl)43- aminoethyl]-{3-ethyl-fl-aminoethanol may be readily prepared by the interaction of an ethylene dihalide with two equivalents of 2-amino-l-butanol. In like manner, the intermediate N,N'-dimethyl and N,N'-diethyl derivatives of N [N(cc ethyl-,B-hydroxyethyl)-fi-aminoethyl]-fi-ethyl- [i-aminoethanol may also be readily prepared by the interaction of an ethylene dihalide with two equivalents of 2- methylamino-l-butanol or Z-ethylamino-l-butanol, respectively. This preparative method is illustrated by Examples 1 and 3 hereinafter. The N-[N-(a-ethyl-,H-hydroxyethyl)-{3 aminoethyl]-, 3 ethyl-B-amino ethanol and its N,N'-dimethyl and N,N-diethyl derivatives may also be conveniently prepared by the interaction of glyoxal with 2-amino-1-butanol, 2-methylamino-1-butanol or 2-ethylamino-l-butanol, respectively, followed by reduction of the Schiif base intermediates with lithium aluminum hydride. This method is illustrated by Example 5 hereinafter. The N,N-dimethyl derivative of N-[N'-(a-ethyl-flhydroxyethyl) -fi-aminoethyl] -/3-ethyl-fl-aminoethanol may also be readily prepared by treatment of N[N-(a-ethyl- B hydroxyethyl) B-aminoethyl]-[3-ethyl-,B-aminoethanol with formaldehyde in concentrated formic acid. This method is illustrated by Example 2 hereinafter. The N,N diethyl derivative of N-[N-(a-ethyl-fl-hydroxyethyD-fl-aminoethyl]-,B-ethyl-fl-aminoethanol may also be readily prepared by treating the N-[N'(a-ethyl-,B-hydroxyethyl)-/3-aminoethyl]-{3-ethyl-,B-aminoethanol with excess acetic anhydride and reducing the intermediate N,N',0,0- tetra-acetyl derivative with lithium aluminum hydride, the O-acetyl functions being removed during the reduction. This method is illustrated by Example 4 hereinafter.
The 0,0'-dimethyl, 0,0-diethyl and 0,0-dibenzyl derivatives of N-[N'-(oc ethyl B-hydroxyethyD-B-aminoethyl]-B ethyl-fl-aminoethanol, N-methyl-N- [N'-methyl- N'-(oc ethyl 18 hydroxyethyl)-fi-aminoethyl]-[i-ethyl-{3- aminoethanol and N-ethyl-N- [N'-ethyl-N- a-ethyl-fi-hydroxyethyl -;3-aminoethy1] -,8-ethy1-B-aminoethanol may be readily prepared by treating the sodium salt of the appropriate ethylenediamine base with methyl iodide, ethyl iodide or benzyl chloride. This method is illustrated by Examples 6, 7, 8, 9 and 10 hereinafter. They are also prepared from N,O-disubstituted 2-aminobutanol using glyoxal or ethylene dichloride.
The dosage units of the drug may contain other inert or medically active materials, for instance, when the dosage unit form is a tablet, pill or granules, there may also be present various binders, fillers or solid diluents. Suitable materials for this purpose may be, for example, starch such as corn starch or sugar such as lactose or sucrose. There may also be present various medically active materials such as, for example, p-amino salicyclic acid. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. The dosage unit form may also have present various flavors, oil of Wintergreen, and excipients such as dicalcium phosphate. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit, for instance, pills or capsules may be coated with shellac, sugar or both. Of course, any material used in preparing the dosage unit form must be pharmaceutically pure and substantially nontoxic in the amounts employed.
The following examples illustrate the preparation of typical symmetrical ethylenediamines of the present invention.
To 227 g. (2.55 moles) of 2-amino-1-butanol was added 100 g. (1.0 mole) of ethylene dichloride. The mixture was heated at reflux and in a few minutes the exothermic reaction required the removal of exterior heating. After 10 minutes, exterior heating was recommenced for an additional 20 minutes. The hot mixture was then treated with 300 ml. of methanol and then cautiously with 84 g. (2.1 moles) of sodium hydroxide in 80 ml. of water. The precipitated sodium chloride was removed by filtration. The excess Z-amino-I-butanol distilled as a light yellow oil at 83-87 C./ 13 mm. The viscous residue distilled at 165-170 C./ 0.6 mm. as a light yellow oil which tended to solidify in the air condenser; yield, 108 g. Recrystallization by dissolving in 80 ml. of hot ethanol, adding about 150 ml. of petroleum ether (B.P. 90-l00 C.), and cooling at C. overnight, gave 64 g. of white crystals melting at 128132.5 C. This, on recrystallization from 100 ml. of 95% ethanol, gave 35 g. of white crystals melting at 135.5136 C. and a second crop of g. melting at 132.5134 C. which is the meso base. Its dihydrochloride melts at 202-203 C.
From the ethanolic filtrates upon addition of 130 ml. of about 4 N ethanolic hydrochloric acid and cooling, there was obtained 55 g. of white crystals melting at 176.5-178 C. and a second crop of 10 g. melting at 171.5-174.5 C.. This is the dl racemate dihydrochloride.
4 Example 2.N-methyl-N- [N -methyl-N'-( a-ethyl-B- hydroxyethyl) -,B-amin0ethyl] -,8-ethyl-,B-aminoethan0l To 16.5 g. (0.36 mole) of 98% formic acid was added 10.0 g. (0.048 mole) of N-[N'-(a-ethyl-B-hydroxyethyl)- fi-aminoet-hyl]-B-ethyl-fl-aminoethanol in portions, with cooling. Then, 9.0 g. (0.105 mole) of 37% formaldehyde was added and the mixture was heated on the steam bath. After evolution of carbon dioxide ceased, refluxing was continued for an additional six hours. The solution was cooled, treated with 15 ml. of cone. HCl and filtered prior to refluxing for 1.5 hours. After vacuum evaporation, the resulting yellow viscous liquid was treated with 25% NaOH and the organic layer extracted into benzene. The combined extracts were dried over anhydrous Na CO and concentrated leaving an oily residue which on distillation under high vacuum yielded the product as a colorless oil, 7.4 g., B.P. 132 134 C./0.01 mm.
A mixture of 33 g. (0.28 mole) of Z-ethylamino-l-butanol and 13.2 g. (0.07 mole) of ethylene dibromide was heated to reflux for 2 hours with a vigorous initial reaction. To the cooled mixture 30 ml. of 10 N NaOH was added and the resulting oil layer was extracted with benzene. After drying over anhydrous Na CO the benzene and excess 2-ethylamino-l-butanol were distilled and the residue, 12 g., distilled at 90130 C./0.02 mm. On redistillation, the product boiled at 135.138 C./ 0.07 mm.
An alternate method of preparing the product of EX- ample 3 is to treat N-[N'-ol-ethyl-fi-hydroxyethyl)-,B- aminoethyl]-fl-ethyl-[3-aminoethanol with excess acetic anhydride to obtain the N,N,0,0'-tetra-acetyl derivative. By reduction of this intermediate with lithium aluminum hydride in diethyl ether at the reflux temperature for a period of several hours, the desired N,N'-diethyl derivative is obtained, the O-acetyl functions being removed during the reaction.
To 6.0 g. (0.03 mole) of 30% aqueous glyoxal was added 9.2 g. of Z-aminobutanol (with moderate heat evolution) and 30 ml. of absolute ethanol. A total of 3.7 g. (0.1 mole) of sodium borohydride was added in portions over 10 minutes. The reaction mixture, after the vigorous reaction had subsided, was heated for 30 minutes. On adding Water and extracting with chloroform, the meso isomer, M.P. 131l34 C., was isolated on cooling. The dl isomer was isolated as the dihydrochloride salt, M.P. 172-175 C. on acidifying the filtrate with ethanolic HCl.
Example 6 .-N ,N -bisa-m ethoxymethylpropyl ethy enediamine To a solution of 21.0 g. of dextro 2,2'-(ethylenediimino)- di-l-butanol in 225 ml. of t-butanol was added a suspension of 9.50 g. of sodium hydride (51.5% NaH in oil) in 30 ml. of ether and the reaction mixture was heated to deflux for 1 hour whereby a clear solution was obtained. This was cooled to 35 C. with some solid forming. Dropwise addition of a solution of 28.0 g. of methyl iodide in 25 ml. of t-butanol caused some temperature rise and a clearing of the solution. The solution was refluxed for 18 hours and the solvent removed under vacuum. Addition of ml. of 6 N hydrochloric acid gave a deep red solution which was extracted with benzene. The aqueous phase was made strongly alkaline with sodium hydroxide causing separation of a red oil. Extraction with benzene followed by drying with anhydrous sodium carbonate and distillation gave a fraction, B.P. 152163 C./ 13' mm, Acidification of the distillate with ethanolic hydrochloric acid, followed by the addition of a large volume of acetone, gave white crystals of dextro N,N'-bis- (a-methoxyrnethylpropyl) ethylenediamine dihydrochloride, M.P. 181-183 C.
Example 7.N,N'-bis- (ot-methoxymethylpropyl) ethylenediamine Example 6 was repeated but an equimolar amount of the racemic form was employed in place of the dextro starting material of that example. There was obtained the racemic N,N-bis-(a methoxymethylpropyl)ethylenediamine dihydrochloride as white crystals, M.P. 148- 150 C.
Example 8.N,N'-bis-(a-methoxymethylpropyl) ethylenediamine By replacing the dex-tro starting material employed in Example 6 by an equimolar quantity of the meso isomer and following substantially the same procedure described in Example 6, there was obtained the meso N,N'-biS-(ocmethoxymethylpropyl)ethylenediamine as a colorless oil, B.P. 144-146 C./13 mm.
Example 9.N,N'-bis-( a-ethoxymethylpropyl ethylenediam'ine The procedure of Example 6 was repeated substituting an equimolar amount of ethyl iodide for the methyl iodide employed in that example. There was thus obtained on distillation dextro N,N-bis-(a-ethoxymethylpropyl) ethylenediamine, B. P. 157160 C./ 8 mm.
Example 10.-N,N'-bis-(ot-benzyloxymethylpropyl) ethylenediamine By replacing the methyl iodide employed in Example 6 by an equimolar quantity of benzyl chloride and following substantially the same procedure described in Example 6, there was obtained the dextro N,N'bis-(a-benzyloxymethylpropyl)ethylenediamine, B.P. 215225 C./ 0.12 mm.
Example 11.N,N-bis-(oz-methoxymethylpropyl) -N,N- dimelhylethylenediamine A solution of 4.1 g. of dl-2,2'-(ethylenediimino)-di-1- butanol in 20 ml. of hot toluene was added dropwise to a suspension of 0.96 g. of sodium hydride in 5 ml. of toluene, the temperature being kept at 100 C. After stirring this mixture for several hours at room temperature, a solution of 6.3 g. of dimethyl sulfate in 5 ml. of toluene was added slowly, keeping the temperature below 50 C. The resulting mixture was treated with water and the toluene layer separated. The water layer was extracted several times with methylene chloride and the combined extracts (toluene and CH Cl were dried over anhydrous sodium carbonate, and concentrated to 50 ml. The concentrate was extracted with dilute hydrochloric acid. The extract was basified, and the insoluble organic layer extracted into CH CI The extract was dried over anhydrous sodium carbonate, concentrated, and the residue distilled under reduced pressure to give the tetramethyl derivative as a liquid fraction, B.P. 95 C./0.01 mm.
What is claimed is:
1. A member of the class consisting of symmetrical ethylenediamines of the formula:
wherein R and R are the same and are selected from the group consisting of hydrogen, methyl and ethyl, and R and R are the same and are selected from the group consisting of methyl, ethyl and benzyl; and the non-toxic acid-addition salts thereof.
2. The compound N,N'-bis-(a-methoxymethylpropyl) ethylenediamine.
3. The compound N,N'-bis-(a-ethoxymethylpropyl) ethylenediamine.
4. The compound N,N'-bis-(a-benzyloxymethylpropyl) ethylenediamine.
5. The compound N,N'-bis-(oc-methoxymethylpropyl)- N,N'-dimethylethylenediamine.
6. The compound N,N'-bis-(a-ethoxymethylpropyn- N,N'-dimethylethylenediamine.
7. The compound N,N-bis-(a-benzyloxymethylpropyl -N,N'-dimethylethylenediamine.
8. The compound N,N'bis-(ot-methoxymethylpropyl)- N,N'-diethylethylenediamine.
9. The compound N,N-bis-(ot-ethoxymethylpropyl)- N,N'-diethylethylenediamine.
10. The compound N,N'-bis-(ot-benzyloxymethylpropyl -N,N-diethylethylenediamine.
References Cited by the Examiner UNITED STATES PATENTS 2,739,981 3/1956 Szabo et al 260-5705 FOREIGN PATENTS 799,057 7/ 1958 Great Britain.
OTHER REFERENCES Boon, Journal Chemical Society London, 1947, pages 307-18.
Swain et al., Journal American Chemical Society, vol. 76, pages 5089-9 (1954).
CHARLES B. PARKER, Primary Examiner.
ROBERT V. HINES, Assistant Examiner.
Claims (1)
1. A MEMBER OF THE CLASS CONSISTING OF SYMMETRICAL ETHYLENEDIAMINES OF THE FORMULA:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US432419A US3271450A (en) | 1962-01-23 | 1965-02-12 | 2, 2'-(ethylenediimino)-di-1-butanols |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US168241A US3176040A (en) | 1961-02-07 | 1962-01-23 | Novel 2, 2'-(ethylenediimino)-di-1-butanols |
US432419A US3271450A (en) | 1962-01-23 | 1965-02-12 | 2, 2'-(ethylenediimino)-di-1-butanols |
Publications (1)
Publication Number | Publication Date |
---|---|
US3271450A true US3271450A (en) | 1966-09-06 |
Family
ID=26863914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US432419A Expired - Lifetime US3271450A (en) | 1962-01-23 | 1965-02-12 | 2, 2'-(ethylenediimino)-di-1-butanols |
Country Status (1)
Country | Link |
---|---|
US (1) | US3271450A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3463861A (en) * | 1961-02-07 | 1969-08-26 | American Cyanamid Co | Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols |
US3956502A (en) * | 1974-09-04 | 1976-05-11 | Nalco Chemical Company | Polyamine alcohols as microbiocides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2739981A (en) * | 1952-08-26 | 1956-03-27 | American Home Prod | Diamines and salts thereof |
GB799057A (en) * | 1955-05-06 | 1958-07-30 | Fulvio Bracco | New sulphur containing compounds and process for the production thereof |
-
1965
- 1965-02-12 US US432419A patent/US3271450A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2739981A (en) * | 1952-08-26 | 1956-03-27 | American Home Prod | Diamines and salts thereof |
GB799057A (en) * | 1955-05-06 | 1958-07-30 | Fulvio Bracco | New sulphur containing compounds and process for the production thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3463861A (en) * | 1961-02-07 | 1969-08-26 | American Cyanamid Co | Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols |
US3956502A (en) * | 1974-09-04 | 1976-05-11 | Nalco Chemical Company | Polyamine alcohols as microbiocides |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS63192758A (en) | 1-(4-hydroxy-3, 5-di-tert-butylbenzoyl) homopiperadine and its derivative | |
JPS62158249A (en) | Antiischemic and manufacture | |
EP0074014B1 (en) | 2-(2'-hydroxy-3'-(1,1,-dimethyl propylamino)-propoxy)-beta propiophenone, its addition salts, process for its preparation and medicaments | |
US3483221A (en) | 1 - (isopropylamino)-2-hydroxy-3-(alkenyloxyphenoxy) - propanes and the salts thereof | |
US3271450A (en) | 2, 2'-(ethylenediimino)-di-1-butanols | |
US4034113A (en) | Treatment of senile geriatric patients to restore performance | |
DE69223835T2 (en) | New aminophenol derivatives and pharmaceutical compositions containing them | |
DE1815808B2 (en) | 1 - (Alkanoylamiitophenoxy) -3-alkylamino-2-propanols, their manufacturing processes and pharmaceutical compositions based on them | |
US3086910A (en) | Central nervous system depressants 3-(2'-pyridyl)-4-quinazolones | |
DE69019294T2 (en) | Triazolyl hydrazide derivatives and process for their preparation. | |
US4018767A (en) | Anti-arrhythmic agents | |
US3268576A (en) | Di-alkanoic acid esters of 2, 2'-(ethylenedhino)-di-1-butanols | |
US3116312A (en) | Substituted-2-cyanoacetanilides | |
US3160664A (en) | Acetylenic omega-haloalkylamines | |
US4034011A (en) | 1,1-Diphenyl-4-(substituted-amino)butanes | |
CA1055044A (en) | Phenylalkyl esters of amino-acids having antidepressive activity | |
US3463861A (en) | Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols | |
US3966779A (en) | Thymol derivatives and a process for their preparation | |
US3297707A (en) | Pyridyl esters of 2, 2'-(ethylenediimino)-di-1-butanols and non-toxic acid addition salts thereof | |
EP0160173B1 (en) | Benzothiazole derivatives, processes for their production and medicaments containing them | |
DE69200179T2 (en) | Thioxanthenone antitumor agent. | |
US3415869A (en) | Dibenzoyl esters of n-(methyl or ethyl)-n-[n'-(methyl or ethyl)-n'-(alpha-ethyl-beta-hydroxyethyl) - beta - aminoethyl] - beta - ethyl-beta-aminoethanol | |
US2878279A (en) | Process of making bis-carbamic acid ester compounds | |
US4317832A (en) | Indolyl and methylindolyl substituted aminoalkyl guanidines | |
DE2213271C3 (en) | NEW OXAZOLIDINS |